Clinical trials: Autologous Transplantation
Lymphoma
Non-interventional Study on TEAM Conditioning in Patients With Lymphoma (TEAM)
Lymphoma is a malignant blood disease sensitive to chemotherapy. In case of relapse after first-line treatment, high-dose chemotherapy conditioning followed by autologous hematopoietic stem cell transplantation (auto-HSCT)…
- Trial name
- TEAM (NCT02504190)
- Where
- France
- Volunteers
- 95 people
- Sponsor
- Association for Training, Education, and Research in Hematology, Immunology, and Transplantation
Electric Stimulation Therapy
Safety and Feasibility of Electrical Muscle Stimulation During Stem Cell Transplantation or Intensive Chemotherapy
Intensive chemotherapy, with or without following autologous or allogeneic stem cell transplantation (HSCT), is often the only curative treatment option for patients with haematological malignancies, leave many survivors…
- Trial name
- NCT03467087
- Testing
- Myopuls 2000D
- Volunteers
- 45 people
- Sponsor
- University Hospital, Saarland
Secondary Hyperparathyroidism
Comparison of Total Parathyroidectomy With and Without Autotransplantation
The purpose of this study is to compare short-term and long-term efficacy of total parathyroidectomy with autotransplantation and total parathyroidectomy without autotransplantation for Secondary hyperparathyroidism.
- Trial name
- NCT02536287
- Testing
- total PTX without autotransplantation, total PTX with autotransplantation
- Where
- China
- Volunteers
- 96 people
- Sponsor
- The Second Hospital of Anhui Medical University
Nonunion Fracture
Allograft vs. Autograft Nonunion
The purpose of this research study is to find out if patients treated for nonunion fracture with autograft or allograft return to activity faster.
- Trial name
- NCT07310082
- Testing
- Autograft, Allograft
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- Wake Forest University Health Sciences
Central Nervous System Lymphoma
Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
This is a multicenter open label randomized phase II trial. Enrolled Primary Central Nervous System Lymphoma (PCNSL) patients will be stratified according to the IELSG score and randomized to receive one of the follows as primary…
- Trial name
- NCT01011920
- Testing
- Methotrexate, Ara-C, Rituximab
- Where
- 54 sites in Denmark, Germany and 3 more
- Volunteers
- 227 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency
Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)
The purpose of this study is to evaluate the Safety and Efficacy of Gene Therapy of the severe combined immunodeficiency (SCID) caused by mutations in the human DCLRE1C gene (Artemis) by transplantation of a single dose of…
- Trial name
- ARTEGENE (NCT05071222)
- Testing
- ARTEGENE drug product
- Where
- France
- Volunteers
- 7 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Premature Ovarian Failure
Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
Stem cells (SC) are the foundation cells for every organ, tissue and cell in the body. They are undifferentiated "blank" cells that do not yet have a specific function.
- Trial name
- NCT02062931
- Testing
- Stem Cell Preparation and Injection
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sayed Bakry
Multiple Myeloma, Amyloidosis
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple…
- Trial name
- NCT04991103
- Testing
- DaraVRD/DaraVCD
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Alabama at Birmingham
Multiple Myeloma, Non-eligible for Autologous Stem Cell Transplantation (ASCT)
Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT
This is a prospective, observational, single group and multicenter study to describe the effectiveness and safety of maintenance with V-Dara after induction with the VMP-Dara regimen in newly diagnosed MM patients who are not…
- Trial name
- NCT05218603
- Testing
- Bortezomib, Daratumumab
- Where
- 32 sites in Spain
- Volunteers
- 100 people
- Sponsor
- PETHEMA Foundation
Lymphoma
Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma
RATIONALE: Giving colony-stimulating factors, such as G-CSF, monoclonal antibodies, such as rituximab, and chemotherapy, such as cyclophosphamide, helps stem cells move from the patient's bone marrow to the blood so they can be…
- Trial name
- NCT00242996
- Testing
- filgrastim, rituximab, sargramostim
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hodgkin Disease, Non-Hodgkins Lymphoma
Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease
Subjects have a type of lymph gland cancer called Hodgkin or non-Hodgkin Lymphoma, which has come back or not gone away after treatment, including the best treatment we know for relapsed Lymphoma.
- Trial name
- ANGELA (NCT00058773)
- Testing
- Infusion of EBV Specific Cytotoxic T-Lymphocytes
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Baylor College of Medicine
Multiple Myeloma, Autologous Transplantation
Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).
This is a long-term observational study of patients that were treated with at least 1 dose of study treatment (plerixafor or placebo) in the AMD3100-3102 protocol (NCT00103662).
- Trial name
- NCT00741780
- Testing
- plerixafor, granulocyte colony-stimulating factor (G-CSF)
- Volunteers
- 164 people
- Sponsor
- Genzyme, a Sanofi Company
Lumbar Degenerative Disc Disease, Lower Back Pain
Human Autograft Mesenchymal Stem Cell Mediated Stabilization of The Degenerative Lumbar Spine
Investigate the potential of tissue grafting that includes human mesenchymal stem cells in the repair and potential stabilization of the degenerative Lumbar disk and facet joint denovo and at the time of surgical reconstruction.
- Conditions
- Lumbar Degenerative Disc Disease, Lower Back Pain, Chronic Lower Back Pain
- Trial name
- NCT02529566
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- The Foundation for Spinal Research, Education and Humanitarian Care, Inc.
Stroke
Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke
The purpose of this study is to evaluate the safety and efficacy of autologous peripheral hematopoietic stem cell transplantation in ischemic stroke.
- Trial name
- AHSCTIS (NCT01518231)
- Testing
- autologous hematopoiesis stem cell transplantation, Aspirin, Warfarin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Hospital
Multiple Myeloma
Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy
Patients 60 to 70 years of age with newly diagnosed multiple myeloma were prospectively randomized between 4 cycles of anthracycline/dexamethasone-based induction chemotherapy (A1) or only 2 x 4 days of dexamethasone (A2).
- Trial name
- DSMM-II (NCT02288741)
- Testing
- Anthracycline/dexamethasone-based induction chemotherapy, Dexamethasone for control of symptoms, Tumor-reduction chemotherapy and stem cell mobilization
- Volunteers
- 549 people
- Sponsor
- WiSP Wissenschaftlicher Service Pharma GmbH
Myeloma Multiple
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
This project will evaluate the efficacy and safety of the conditioning regimen bortezomib-bendamustine-melphalan (BBM) in combination with autologous hematopoietic stem cell transplantation (ASCT) in relapsed multiple myeloma…
- Trial name
- NCT06245629
- Testing
- Bortezomib-bendamustine-melphalan
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Uppsala University
Multiple Myeloma
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara
This protocol is a phase II multicenter, randomized, open label study designed to assess the efficacy and safety of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone (Dara-VCd) versus the association of…
- Trial name
- NCT03896737
- Testing
- Daratumumab plus Velcade Cyclophosphamide Dexamethasone, Velcade Thalidomide Dexamethasone
- Where
- 24 sites in Czechia, Greece and 1 more
- Volunteers
- 401 people
- Sponsor
- European Myeloma Network B.V.
Osteoarthritis of the Knee
Autograft Versus Calcium Phosphate Macroporous Bioceramics as Bone Substitute for Tibial Valgus Osteotomy
The aim of the study is to compare radiological behavior of blocks of macroporous phosphocalcium as bone substitute in comparison with iliac crest autograft in tibial valgus osteotomy.
- Trial name
- NCT00200603
- Testing
- calcium phosphate macroporous bioceramics
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Nantes University Hospital
Diffuse Large B Cell Lymphoma
Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive
To evaluate the efficacy and safety of selinexor combined with BEAM pretreatment regimen in ASCT of recurrent and refractory DLBCL patients with immunohistochemical positive for MYC
- Trial name
- NCT06652139
- Testing
- selinexor combined with BEAM regimen, BEAM regimen
- Volunteers
- 82 people
- Sponsor
- Ruijin Hospital
Rejection; Transplant, Liver, Liver Failure
Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients
The purpose of this study is to evaluate the safety and tolerability of QEL-001 in the prevention of liver transplant rejection following immunosuppression withdrawal.
- Conditions
- Rejection; Transplant, Liver, Liver Failure, Liver Diseases
- Trial name
- LIBERATE (NCT05234190)
- Testing
- QEL-001
- Where
- 10 sites in Belgium, Spain and 1 more
- Volunteers
- 33 people
- Sponsor
- Quell Therapeutics Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.